SCHEMBL4099223

SCHEMBL4099223

COc1ccc(N2CCC(N3CCN(C)CC3)CC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)N(C)C)n1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 14/20 0.77
IGF1R P08069 13/20 0.77
INSR P06213 13/20 0.77
EGFR P00533 8/20 0.63
MET P08581 4/20 0.63
LCK P06239 4/20 0.63
FYN P06241 4/20 0.63
FLT3 P36888 4/20 0.63
PTK2 Q05397 4/20 0.63
PTK6 Q13882 4/20 0.63
PTK2B Q14289 4/20 0.63
PRKD2 Q9BZL6 4/20 0.63
PLK1 P53350 4/20 0.63
FGFR1 P11362 4/20 0.63
FGFR3 P22607 4/20 0.63
PLK4 O00444 3/20 0.63
EPHA2 P29317 3/20 0.63
LIMK1 P53667 3/20 0.63
AURKB Q96GD4 3/20 0.63
SLK Q9H2G2 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4094604 0.91 ALK (0.72) ALKIGF1RINSREGFRMET
SCHEMBL4100866 0.89 ALK (0.66) ALKIGF1RINSREGFRMET
SCHEMBL4088361 0.86 ULK1 (0.72) ALKIGF1RINSREGFRMET
SCHEMBL2824945 0.85 ALK (0.81) ALKIGF1RINSREGFRMET
SCHEMBL4099002 0.83 ULK1 (0.79) ALKIGF1RINSREGFRMET
SCHEMBL4100115 0.83 ALK (0.63) ALKIGF1RINSREGFRMET
SCHEMBL12892782 0.82 ALK (0.89) ALKIGF1RINSREGFRMET
SCHEMBL12312367 0.82 ULK1 (0.81) ALKIGF1RINSREGFRMET
SCHEMBL4103561 0.81 ULK1 (0.67) ALKIGF1RINSREGFRMET
SCHEMBL886637 0.81 ALK (0.79) ALKIGF1RINSREGFRMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 US claimed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP claimed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO claimed
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 US disclosed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP disclosed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131436-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS ALK 2060/4885IGF1R 4608/4885INSR 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.